Tag: Taspoglutide

Roche logo

Roche drug may offer valuable new treatment option for patients with type 2 diabetes

Roche announced today that results from the first five Phase III clinical trials show that taspoglutide has met the primary end-points of reduction in blood glucose in these studies. Roche’s taspoglutide, the first weekly human GLP-1 analogue in late stage development may improve treatment options for patients with type 2 diabetes...
0 Shares
Roche-logo

Phase III Trials Show Roche’s Type 2 Drug Better Than Januvia

The Swiss -based pharmaceuticals and diagnostics company Roche Holding AG announced headline results from the second and third of eight T-emerge Phase III studies for taspoglutide. Taspoglutide is the first once-weekly human glucagon-like peptide-1 (GLP-1) analogue being developed to address the important unmet needs of patients with type 2 diabetes....
0 Shares